---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-22-000076"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:58:54.726372+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q3 revenue $5.1M (+13% YoY); reaffirms FY2022 guidance

## Summary
- Revenue of $5.1M, up 13% YoY; gross margin improved to 72% from 66%.
- Cash and short-term investments $40.5M at Sept 30, 2022; reaffirms FY2022 revenue $21-22M.
- Partner PTC's Upstaza gene therapy approved in EU; SmartFlow Neuro Cannula included in label.
- Added ~50 biologics/drug delivery partners; installed record 10 new systems YTD.
- FDA cleared ClearPoint Maestro Brain Model, Prism Neuro Laser Therapy, and navigation software v2.1.

## SEC filing metadata
- accession: 0001285550-22-000076
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/0001285550-22-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/clpt-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-22-000076
- JSON: https://secwatch.observer/filing/0001285550-22-000076.json
- Plain text: https://secwatch.observer/filing/0001285550-22-000076.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported third quarter ended September 30, 2022 results: revenue $5.1 million. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Revenue: $5.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022. Third Quarter Highlights • Reported quarterly revenue of $5.1 million, a 13% year-over-year increase; • Partner PTC Therapeutics’ gene therapy treatment Upstaza TM was granted full marketing authorization by the European Commission. Upstaza will be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/0001285550-22-000076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.